SAN FRANCISCO, May 02, 2019 (GLOBE NEWSWIRE) -- Today ProLynx LLC announced a second collaboration with Daiichi Sankyo Company, Limited to utilize its drug delivery linker technology to extend the intravitreal half-life of Daiichi Sankyo’s drug candidates.

The ProLynx half-life extension technology tethers a drug to a carrier by a self-cleaving b-eliminative linker programmed to release the drug at a pre-determined rate; after injection, the drug is slowly released from the carrier depot. Previously, ProLynx and Daiichi Sankyo showed that the technology could be used to greatly prolong the residence time of small molecule drugs in the eye.

Daniel Santi, co-founder and President of ProLynx, said: “Recently, ProLynx and Daiichi Sankyo published a novel technology for intra-vitreal half-life extension of small molecule drugs. We can convert drugs that normally have half-lives of hours in the eye to a formulation that may only require once-monthly injections.” Added Santi: “Now, we are collaborating to apply our technology to create long-acting versions of Daiichi Sankyo’s drug candidates for treatment of an important eye disease”.

About ProLynx. ProLynx LLC is a privately held biotechnology company developing proprietary drug delivery systems for half-life extension of proteins, peptides and small molecules. The company is seeking to apply its technology to extend half-lives of drug candidates of pharmaceutical companies, and to improve properties of off-patent therapeutics. The company is located in San Francisco, CA. For further information visit: www.ProLynxllc.com.

About Daiichi Sankyo. Daiichi Sankyo Company is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases.
For more information, please visit: www.daiichisankyo.com.

Eric Schneider: Eric@ProLynxllc.com or
BD@ProLynxllc.com
+1 415-552-5306